News

The lack of details about which countries are involved and which companies will be impacted as a result of the new trade deal ...
A NEW Phase 3 trial has shown that a combination therapy of cagrilintide and semaglutide (CagriSema) can lead to substantial ...
July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...
Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% loss and strong cardiometabolic benefits ...
CagriSema is delivered as a once-weekly subcutaneous injection, like Wegovy and Zepbound, and Novo Nordisk also presented data at ADA on its oral weight-loss candidate amycretin, which combines ...
In December, Novo Nordisk reported that CagriSema was able to muster a 22.7% weight loss at 68 weeks in REDEFINE 1, which also fell short of its hoped-for reduction of 25%.
See the latest Novo Nordisk AS ADR stock price (NVO:XNYS), related news, valuation, dividends and more to help you make your investing decisions.
A high-level overview of Structure Therapeutics Inc. (GPCR) stock. View (GPCR) real-time stock price, chart, news, analysis, analyst reviews and more.
ADA 2025 Significant Weight Loss With CagriSema, but Less Than Hoped Experts said that the novel combination of a GLP-1 and amylin analogue will help obese patients with and without diabetes ...